Pancreatic cancer - the past, the present, and the future.
Scand J Gastroenterol
; 57(10): 1169-1177, 2022 10.
Article
en En
| MEDLINE
| ID: mdl-35477331
ABSTRACT
BACKGROUND:
Pancreatic cancer has been and still is associated with a very poor prognosis. This is due to a lack of major breakthroughs with respect to early diagnosis, prognostication, prediction, as well as novel, targeted therapies. The benefits of surgery and chemotherapy are evident, but the fact that only some 10% of all patients have early, localized disease highlights the unmet need for new early detection methods. An improved understanding of tumor biology and the development of molecular markers detectable both in the circulation and in cancer tissues may underlie the development of new tools for optimizing both diagnosis and treatment. MATERIAL ANDMETHODS:
Review of the literature. RESULTS ANDCONCLUSION:
If we do not improve precision oncology for pancreatic ductal adenocarcinoma, the prognosis will still remain dismal and the" burden" on society will increase substantially.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias Pancreáticas
/
Carcinoma Ductal Pancreático
Tipo de estudio:
Diagnostic_studies
/
Screening_studies
Límite:
Humans
Idioma:
En
Revista:
Scand J Gastroenterol
Año:
2022
Tipo del documento:
Article
País de afiliación:
Suecia